TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03934645

Intervention type: OTHER
Intervention: Delirium prediction model for ICU patients, version 1
Description: The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.

Intervention type: OTHER
Intervention: Delirium prediction model for ICU patients, version 1
Description: The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.

Intervention type: OTHER
Intervention: Delirium prediction model for ICU patients, version 2
Description: The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.

Intervention type: OTHER
Intervention: Delirium prediction model for ICU patients, version 2
Description: The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.

Intervention type: OTHER
Intervention: Early prediction model for delirium in ICU patients
Description: The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.

Intervention type: OTHER
Intervention: Early prediction model for delirium in ICU patients
Description: The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
Study: NCT01062477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP//PRP-T Combined Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT02474368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Study: NCT00646932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 0.04 mcg/kg three times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 0.08 mcg/kg three times a week
Study: NCT00646932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 0.16 mcg/kg three times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 0.24 mcg/kg three times a week
Study: NCT01062477

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine
Description: 0.5 mL, Intramuscular (each vaccine)
Study: NCT01490593

Intervention type: BEHAVIORAL
Intervention: Public Health strategies
Description: It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
Study: NCT03638492

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2-cm margin
Description: Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4-cm margin
Description: Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
Study: NCT00486902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
Study: NCT02474368

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Study: NCT03396289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy including balance exercises
Description: Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy including balance exercises
Description: Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
Study: NCT02478567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Training
Description: four specific band-resisted strength training exercises for scapula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Training
Description: four specific band-resisted strength training exercises for rotator cuff
Study: NCT01869309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
Study: NCT03396289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
Study: NCT03378570

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
Study: NCT00704470

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical simulator training
Description: Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator based crew resource management course
Description: Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
Study: NCT02123914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with Vit. C
Description: walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
Study: NCT04406571

Intervention type: OTHER
Intervention: Data record
Description: Data record

Intervention type: OTHER
Intervention: Data record
Description: Data record
Study: NCT02363829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT03819075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lightwalker Laser (Fotona)
Description: For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
Study: NCT02314806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation with gentamicin solution
Description: The surgical bed is irrigated with a gentamicin solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation with Clindamycin solution
Description: The surgical bed is irrigated with a clindamycin solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irrigation with Normal saline
Description: The surgical bed is irrigated with normal saline
Study: NCT03735485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program.
Study: NCT02123914

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise with Vit. C
Description: walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
Study: NCT04503733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q4W GMA301 IV injections (300 mg)
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Study: NCT02154594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acacia catechu

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acacia catechu
Study: NCT04503733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q4W GMA301 IV injections (600 mg)
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q4W GMA301 IV injections (1000 mg)
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q4W GMA301 IV injections (1800 mg)
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Study: NCT02154594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acacia catechu
Study: NCT04503733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Q4W placebo IV injections
Description: Placebo is indistinguishable from GMA301.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Q4W placebo IV injections
Description: Placebo is indistinguishable from GMA301.
Study: NCT02154594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Study: NCT01837576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus BDP gel in different doses
Description: Topical , Once daily, 3 weeks
Study: NCT00709579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RV3391A
Description: A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02154594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine gluconate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distilled water
Study: NCT01869309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
Study: NCT02197156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg HC-ER
Description: Single dose
Study: NCT02154594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distilled water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Study: NCT00687453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine at bedtime instead of NPH
Description: Insulin glargine at bedtime substituting for NPH insulin at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH twice-daily
Description: Addition of morning NPH to bedtime NPH
Study: NCT01596179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive navigational support
Description: Interactive navigational support is provided by a nurse and social worker navigators
Study: NCT02051075

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PXN sperm treatment
Description: immotile sperm activation with PXN

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sperm activation with PXN and oocyte activation
Study: NCT01920646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALV
Description: Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
Study: NCT01311869

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EGCG ( Green Tea extract)
Description: A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG ( Green Tea extract)
Description: A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Brown rice pills
Description: 40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brown rice pills
Description: 40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
Study: NCT03735485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder Mobilization
Description: In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist.
Study: NCT03301948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeed
Description: Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
Study: NCT01596179

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet access
Description: a netbook computer with internet access is provided to participants on the control arm.
Study: NCT01249235

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patch or bandage contact lens
Description: Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patch or bandage contact lens
Description: Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
Study: NCT00864760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg tablets, single dose (1 tablet)
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 400 mg capsules, single dose (2 capsules)
Description: B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
Study: NCT01451593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo identical in appearance to active IMP (phenytoin)